rejuvant life tabs

New immune aging drug brings Longevity and C19 hope

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

Phase 2-ready drug can treat and reverse immune aging, BioAge claims.

BioAge Labs‘ in-licensed clinical-stage therapy has potential for treating immune aging in older patients hospitalised with COVID-19, tackling both morbidity and mortality, the biotech company claims.

Longevity.Technology: Back in May we covered BioAge Labs’ exclusive worldwide licence agreement with Taisho Pharmaceutical to develop and commercialise Taisho’s clinical-stage HIF-PH inhibitor to target multiple diseases of aging.

Not resting on their laurels at all, the company is responding to the global pandemic with a drug that has the potential to treat immune aging in older patients hospitalised with COVID-19. But the research has wider ramifications, as one of the key effects of aging is the dysregulation of the immune system caused by immunosenescence and inflammaging; being able to correct that dysregulation would significantly benefit both healthspan and lifespan.

BioAge’s compound, BGE-175, is an orally-administered inhibitor of the prostaglandin D2 DP1 signalling pathway associated with increased risk of mortality, and susceptibility to infections. The company recently generated preclinical data showing significant immune-modulating and anti-viral activity of BGE-175 which resulted in 100% survival in a preclinical model of the SARS 1 virus.

 


 

BioAge Labs revealed that in addition to fully-protecting infected mice from death and improving morbidity, treated mice showed a 10-fold decrease in virus in their lungs.

 


 

In a statement, BioAge Labs revealed that in addition to fully-protecting infected mice from death and improving morbidity, treated mice showed a 10-fold decrease in virus in their lungs. BGE-175 has demonstrated clinical activity and safety in a large number of subjects across multiple clinical trials for another indication.

Elevant

“Aging is the largest risk factor for COVID-19 morbidity and mortality,” said Kristen Fortney, PhD, BioAge’s CEO. “BGE-175 has the potential to restore the function of several key immune mechanisms that become dysregulated with aging, and that are critical to mount an effective response to major immune challenges such as COVID-19, SARS, and pandemic influenza. We plan to advance BGE-175 into a Phase 2 clinical trial in COVID-19 patients to evaluate whether its unique mechanism can improve patient outcomes by directly targeting immune aging.”

 


 

“… the potential to address other diseases driven by immune aging … a growing pipeline of promising therapeutics that BioAge will bring forward to treat diseases of aging.”

 


 

Dr Fortney added: “Our AI-driven analysis of our proprietary human aging data maps out how the immune system is dysregulated during aging. Beyond COVID-19, BGE-175 has the potential to address other diseases driven by immune aging. BGE-175 is the second in a growing pipeline of promising therapeutics that BioAge will bring forward to treat diseases of aging.”

Elevant

The pathways impacted by BGE-175 are linked to lifespan and healthspan in BioAge’s proprietary human aging data. The prostaglandin pathway, as well as several key components of the immune response to viral challenge, are significantly associated with Longevity and multiple functional measures. Inhibition of PGD2 DP1 receptor signaling impacts multiple immune mechanisms, and BioAge’s preclinical studies demonstrate that BGE-175 inhibits neutrophil migration and that DP1 inhibition boosts dendritic cell function, both of which counteract known aspects of immune aging, and are also therapeutically promising for COVID-19 and other respiratory infections.

We’ll be speaking to Dr Fortney next month to find out about the next steps for BGE-175 and what else is in the BioAge pipeline.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Building a longevity biotech from scratch

Alchemab exec talks company creation and how antibody therapeutics may play a role in longevity biotech. Last week, we covered Alchemab Therapeutics’ $82 million Series...

Muhdo & ARK-KCL collaborate on consumer epigenetic tests

Muhdo partner with King's College London in an advanced research project around epigenetics, AI and informatics. Muhdo has announced it will be partnering with Ageing...

Cellino: longevity powered by AI, stem cells & democracy

From a serendipitous meeting of minds to laser-enabled precision, Cellino is leveraging AI and pluripotent stem cells for longevity. We speak to CEO and...
Supps report ad middle